Cosmo Feilding Mellen is CEO at Beckley Psytech and a drug development entrepreneur dedicated to unlocking the medical potential psychoactive substances, in order to help patients in need.
Cosmo has worked closely with the Beckley Foundation for over 10 years and in 2016 he co-founded Beckley Research & Innovations to develop ethical business models focused on psychedelic research. Cosmo subsequently served as Co-founder and Managing Director of Beckley Canopy Therapeutics, a cannabis-based drug development company that was acquired by Canopy Growth Corporation.
Cosmo received a Double First-Class degree from Oxford University and has previously directed two feature documentaries on Netflix about international drug policy and the history of psychedelics in America.
